The way grants are doled out leads researchers to play it safe -- and that's why there has been little progress in the "war on cancer," writes Gina Kolata in the New York Times. Incremental research is chosen by reviewers because "with too little money to finance most proposals, they are timid about taking chances on ones that might not succeed," Kolata writes.